Artemether-Lumefantrine Clinical Effectiveness Study
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- Adequate Clinical and Parasitological Response (ACPR)
研究概览
简要总结
In 2009, Papua New Guinea officially adopted artemether-lumefantrine (AL) as new national first-line drug for uncomplicated malaria. The principal purpose of this study is to measure the absolute effectiveness of AL when used under real-life clinical conditions, as compared to optimized in-vivo trial conditions. This question was raised by the National Department of Health in preparation for the country-wide roll-out of AL.
The study is designed as a randomized controlled trial comparing two study arms. Patients in the "effectiveness arm" receive the first dose of AL under full supervision in the clinic; the following doses will be taken at home, as in real-life clinical practice and according to the new national treatment guidelines. Patients in the "efficacy arm" will receive all doses of AL as directly observed treatment in the clinic in order to establish the efficacy of the drug when used under ideal conditions.
The study will enroll outpatients aged 6 months to 10 years with a history of fever and a positive rapid test for malaria. Patients meeting all enrollment criteria and providing full written informed consent by a parent/caretaker will be randomized into either of the two study arms. Patients in both arms will be followed up actively for 42 days. Patients in the efficacy arm will be scheduled for visits on days 0, 1, 2, 3, 7, 14, 28 and 42; patients in the effectiveness arm on days 0, 3, 7, 14, 28 and 42.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 6 months to 10 years (+/- 1 month for children without known date of birth)
- •Permanent resident in the study area
- •Not enrolled in another study at the same time
- •No known history of hypersensitivity reactions to artemether or lumefantrine
- •History of fever in the previous 72 hours (approximate)
- •Rapid diagnostic test (RDT) positive for any species of Plasmodium
排除标准
- •General danger signs: inability to drink or breastfeed, vomiting everything, recent history of convulsions, lethargy or unconsciousness, inability to sit or stand up
- •Signs of severe malaria (impaired consciousness, respiratory distress, circulatory collapse, abnormal bleeding, jaundice, or as determined by clinician)
- •Severe malnutrition: defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/WHO normalized reference values, or who has symmetrical oedema involving at least the feet; or middle upper arm circumference under 12 cm
- •Clinically significant concomitant disease requiring admission
- •Contraindications mentioned in the national treatment guidelines
研究组 & 干预措施
Efficacy arm
Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
干预措施: Artemether-lumefantrine combination (Drug)
Effectiveness arm
Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
干预措施: Artemether-lumefantrine combination (Drug)
结局指标
主要结局
Adequate Clinical and Parasitological Response (ACPR)
时间窗: 42 days
ACPR = Absence of parasitemia on Day 42 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure (adapted from WHO 2003).
次要结局
未报告次要终点